|
|
|
Please choose a year to see the respective press releases.
Agendia’s MammaPrint® Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
Thursday, 18 September 2008
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, September 18, 2008 -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint®, has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare Improvement CBO. The CBO guidelines, which ...
Read more |
Agendia Launches TargetPrint for Breast Cancer Patients
Optimizing Patient Identification for Targeted Therapies
That Ensure Benefits of Personalized Treatment
Thursday, 04 September 2008
HUNTINGTON BEACH, CA, and AMSTERDAM, The Netherlands, September 4, 2008 / Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint®, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human ...
Read more |
Agendia and Ferrer announcs exclusive agreement for sales of cancer diagnostic services in four major european markets
Tuesday, 15 July 2008
AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15, 2008 / Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia’s signature cancer diagnostic services.
MammaPrint, a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, ...
Read more |
Agendia expands laboratory capacity at new amsterdam headquartes to meet increasing demand for services worldwide
Thursday, 19 June 2008
AMSTERDAM, The Netherlands, June 19, 2008 / Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. ...
Read more |
MammaPrint Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
Friday, 30 May 2008
CHIGACO, USA, May 30, 2008 / Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced today that data from two studies involving its MammaPrint breast cancer prognosis test will be presented at the American Society of Clinical Oncology’s (ASCO) annual meeting. Collectively, these findings ...
Read more |
Agendia and Agilent Announce Plans to Jointly Develop
New Diagnostic Tests, Extend Supply Agreement
Tuesday, 22 April 2008
AMSTERDAM, The Netherlands and SANTA CLARA, CA (USA), April 22, 2008 / Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, and Agilent Technologies, Inc. (NYSE: A), today announced terms under which they intend to collaborate to develop new in-vitro diagnostic tests. In addition, the ...
Read more |
Agendia appoints oncologist Richard A. Bender as vice president and chief medical officer
Tuesday, 01 April 2008
Leader in Molecular Cancer Diagnostics Strengthens U.S. Management
Along With U.S. Presence
AMSTERDAM, The Netherlands, April 1, 2008 / Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, today announced the appointment of Richard A. Bender, MD, FACP to the position of vice ...
Read more |
Test for gene expression optimizes therapy planning
Tuesday, 19 February 2008
AMSTERDAM, The Netherlands, February 19, 2008 / Agendia BV,
Breast cancer is the most common cancer in women worldwide. If breast cancer is diagnosed at an early stage, the survival rate is currently over 70 percent. However, about 30 percent of stage I and II breast cancer patients develop metastases ...
Read more |
|
|
|
Press Room